SCHEDULE: RA Capital Exits Avidity Biosciences Position

RA Capital Management and its affiliates have reported a 0% beneficial ownership stake in Avidity Biosciences, Inc. as of March 31, 2026.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. filed an amendment to their Schedule 13G.
• The reporting persons disclosed that they no longer beneficially own any shares of Avidity Biosciences, Inc. common stock.
• The filing confirms a 0.0% ownership stake as of the event date of March 31, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative event, as the complete exit of a specialized healthcare fund often signals a shift in institutional support for the company.

Positives

• The filing provides transparency regarding the complete divestment of the reporting persons' position in the issuer.

Negatives

• The exit of a significant institutional investor like RA Capital may be perceived as a lack of long-term confidence in the issuer's immediate growth prospects.

Risks

• Potential negative market sentiment resulting from the departure of a major healthcare-focused investment firm.

Future Outlook

No future outlook or guidance is provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that institutional exits from biotech firms are common as funds rebalance portfolios or reach the end of their investment thesis, though such moves can trigger short-term volatility in smaller-cap stocks.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for institutional investors reporting a change in beneficial ownership below the 5% threshold or total exit.

Stakeholder Impact

• Shareholders may experience increased volatility due to the removal of a major institutional holder.

Next Steps

• None mentioned.

Key Dates

Keywords

Avidity Biosciences, RA Capital Management, Schedule 13G, Divestment, Institutional Ownership, Biotech